Ann: SAVR Clinical Trial, page-72

true. been a long time holder but havent really commented for years. i always wanted the distribution to be handled by someone else and its great now to have a fixed profit margin and reduced overheads. the capital raising for non-R&D expenditure (primarily wages) was the cause of so much dilution. Now we can concentrate on manufacturing and R&D and have a leaner operation. this is a good step to improving cashflow. the recent order (albeit including stock at the time of sale) will add further to the coffers. if this order is planned for a years worth of sales, then Wayne can more easily set a scenario that is less likely to need a raise. budget and forecast with more accuracy.

Id like to know the following if an y of you know:

1 - how staff break cost affected cashflow in the previous
two quarters and whats left to come
2 - what other divestment costs are there (breaking leases, office write offs).
3 - what is the marketing requirements from this distribution sale? all the global conference? the trial doctors? etc. who is responsible for drumming up these costs? im sure its contracted
4 - what costs are included/excluded from the 20% margin? what was our equivalent margin on ssles over the previous 6/12 months?
5 - what operational cost savings can we expect from the divestment?

im certainly feeling better about AHZ but until im clear on the above then i wont sure cashflow can/will be managed.